Leeds-based liquid medicines firm Rosemont Pharmaceuticals saif it acquired Sabal Therapeutics and its affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health, a group of privately owned companies based in Georgia in the United States.

“This acquisition further enhances Rosemont’s ability to serve patients with swallowing difficulties across the USA,” said Rosemont.

“Previously, Rosemont has developed, registered and supplied medicines to the US market via distribution partners.

“This acquisition now provides the company with the ability to supply branded and generic medicines directly into the US market.

“In addition to the existing portfolio included in this transaction, Rosemont has an extensive pipeline of novel, liquid medicines designed for the US market and patients.”

Rosemont CEO Howard Taylor said: “Acquiring Sabal is a key milestone for Rosemont to commercialise our world class medicines to help US patients with swallowing difficulties, building on our platform of high-quality development teams in both the UK and Greece.

“Our Vice President for the US Market, John Denman, who heads our Rosemont Inc US operations, will be leading this venture and all of us at Rosemont are looking forward to working with the Sabal team.”

Sabal CEO Jeff Bryant said: “This fusion of Rosemont and Sabal allows us to greatly expand our vision across therapeutic areas, with the ultimate mission of changing patients’ lives for the better.

“We are delighted to join the Rosemont team to deliver even greater value to our providers and those in their care.”

As of 2024, Rosemont has a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including over 100 licensed products in 27 international markets.